Silence Therapeutics, a biotechnology company working to silence diseases through precision engineered medicines, will receive a $4 million cash payment from Hansoh Pharmaceutical Group  following the achievement of two undisclosed preclinical milestones. Silence and Hansoh entered a collaboration in October 2021 to develop siRNAs (“short interfering RNAs”) leveraging Silence’s mRNAi GOLD platform for three undisclosed targets. Under the agreement, Silence has exclusive rights to the first tw...